Last reviewed · How we verify

NCT05054504: FAB-IQ

Feasibility and Acceptability of Butterfly iQ

Completed NA Last updated 9 April 2024
What this trial tests

NA trial testing Butterfly iQ in Pregnancy Related in 1,575 participants. Completed in 15 March 2024.

Timeline
6 October 2021
Primary endpoint
15 March 2024
15 March 2024

Quick facts

Lead sponsorJhpiego
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposehealth services research
Enrollment1,575
Start date6 October 2021
Primary completion15 March 2024
Estimated completion15 March 2024
Sites1 location across Malawi

Drugs / interventions tested

Conditions studied

Sponsor

Jhpiego — full company profile →

Who can join

18 and older, any sex, with Pregnancy Related. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate feasibility and acceptability of a novel intervention to integrate Butterfly IQ into antenatal care (ANC) service delivery in Malawi. The study will also explore potential impact of the intervention on selected service delivery outcomes and identification of abnormal pregnancies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Butterfly iQ

Trials testing the same drug.

Other recruiting trials for Pregnancy Related

Currently open trials in the same condition.

Other Jhpiego trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05054504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing